RxDoctor Payments Data

Hamid Danesh, MD

Internal Medicine · Lowell, MANPI 1811961196

Payments from drug & device makers

$1,442in general payments, 2019–2025

Across 72 payments — averaging $20.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$303
  • Lilly USA, LLC$123
  • Indivior Inc.$117
  • GSK$115
  • Pfizer$107
  • Inspire Medical Systems, Inc.$69
  • plus $609 from 17 others

What the payments were for

  • Food & beverage$1,40798%
  • Education$352%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,442 in reported general payments places this provider in the 85th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$59,776
Medicare patients
112
Services billed
618

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide85$106,710
OzempicSemaglutide87$82,788
EliquisApixaban84$79,537
JanuviaSitagliptin Phosphate59$64,165
JardianceEmpagliflozin62$49,930
BiktarvyBictegrav/Emtricit/Tenofov Ala11$49,929
SublocadeBuprenorphine13$26,013
XareltoRivaroxaban20$24,271
SuboxoneBuprenorphine Hcl/Naloxone Hcl43$20,740
OxycontinOxycodone Hcl26$19,234
LinzessLinaclotide27$15,771
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl96$13,198
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,327
TradjentaLinagliptin14$8,321
Varenicline Tartrate25$8,041

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$123$106,71085 claims
Novo NordiskOzempic$39$82,78887 claims
PfizerEliquis$107$79,53784 claims
Boehringer IngelheimJardiance, Tradjenta$55$58,25276 claims
GileadBiktarvy$303$49,92911 claims
Indivior Inc.Sublocade, Suboxone$117$46,75256 claims
AbbVieLinzess$37$15,77127 claims
GSKTrelegy Ellipta, Incruse Ellipta$115$11,62225 claims
AstraZenecaSymbicort$53$5,35224 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Lowell

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →